Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Mingliang Wang
Fudan University - Department of Radiology
Shanghai
China
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
77
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Bevacizumab Plus Chemotherapy versus Chemotherapy Alone As First-Line Treatment for Patients with
RAS
Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Single Center Randomized Control Trial
Number of pages: 43
Posted: 29 Dec 2019
Wentao Tang
,
Li Ren
,
Qinghai Ye
,
Ye Wei
,
Guodong He
,
Qi Lin
,
Xiaoying Wang
, Mingliang Wang,
Yuehong Cui
,
Tianshu Liu
and
Jianmin Xu
Fudan University - Department of General Surgery, Fudan University - Department of General Surgery, Fudan University - Department of Liver Surgery and Transplantation, Fudan University - Department of General Surgery, Fudan University - Department of General Surgery, Fudan University - Department of General Surgery, Fudan University - Department of Liver Surgery and Transplantation, Fudan University - Department of Radiology, Fudan University, Zhongshan Hospital, Department of Oncology, Fudan University, Zhongshan Hospital, Department of Oncology and Fudan University - Colorectal Cancer Center
Downloads
77
(823,616)
View PDF
Download
Abstract:
Bevacizumab; RAS mutant; unresectable; colorectal liver-limited metastases
Feedback
